Tarceva avastin trial

Ramaprasad Srinivasan, a principal investigator at the National Cancer Institute, said in a pre-recorded presentation of the data. There are no data from prospective trials of systemic therapy and no established standard of care for these patients, according to Srinivasan.

To assess the safety and efficacy of Avastin in combination with Tarceva, Srinivasan and colleagues enrolled patients into two independent, parallel cohorts. Patients enrolling in the study could have received any number of prior therapies; however, they were restricted to two regimens of previous VEGF-targeting therapies. Additionally, patients could not have received any prior Avastin to treat their disease. Measuring the overall response rate, or the proportion of patients who experienced complete or partial responses to treatment, was the main goal of the study.

Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies A Study of Tarceva vs. Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Recruitment status was: Recruiting First Posted : April 24, Last Update Posted : September 11, Study Description.

Detailed Description:. Drug Information available for: Erlotinib hydrochloride Erlotinib Bevacizumab. Avastin has been shown to improve treatment outcomes in selected patients with advanced colorectal, breast, and non—small cell lung cancer.

Avastin is also being evaluated among patients with earlier-stage cancer, and among patients with other types of cancer. Tarceva is targeted anticancer drug that works by blocking a biological pathway referred to as the epidermal growth factor receptor EGFR pathway.

The EGFR pathway is involved in cell growth and replication and when mutated or altered, excessive replication of cells can occur.

Tarceva has been shown to improve treatment outcomes in selected patients with advanced non—small cell lung cancer or pancreatic cancer, and is also being evaluated in the treatment of other types of cancer. Who is at risk of developing lung cancer?

New lung cancer screening guidelines updated - July Local ablative treatment combined with immunotherapy improves long term survival in oligometastatic NSCLC. To evaluate the combination of Avastin and Tarceva among patients with advanced hepatocellular carcinoma, researchers conducted a Phase II clinical trial. Combination therapy produced a statistically significant Median and one-year survival in the combination treatment arm were 6.

Progression-free survival was also statistically significantly greater in the combination treatment arm. Consistent with the other clinical trials rash and diarrhoea were the main treatment-related side effects associated with administration of Tarceva. Other indications in which Tarceva has produced objective evidence of anti-tumour activity in patients failing standard chemotherapy include ovarian cancer as well as cancers of the head and neck.

Many of the cancers in which EGFR inhibitors are being explored as potential treatment represent difficult-to-treat indications where rates of chemo-resistance and mortality are very high. Cancers of the lung and pancreas in particular represent a large and under-penetrated market, for which drugs such as Tarceva will find a ready place.

Therapy Class Anti-neoplastic agent. Over expression of EGFR is common in many solid tumours. Source: ABPI.